Franck MORIN
Intergroupe Francophone de Cancerologie Thoracique
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Franck MORIN as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04233021 · Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationIntergroupe Francophone de Cancerologie Thoracique · completed · Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:12 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.Mol Cancer Ther · 201274 citationsRCR 2.1
- Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.J Clin Oncol · 202272 citationsRCR 4.2
- 57 citationsRCR 1.6
- 51 citationsRCR 2.9
- Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.J Clin Oncol · 201450 citationsRCR 1.3
- An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.Clin Cancer Res · 201248 citationsRCR 1.2
- A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).Eur J Cancer · 201340 citationsRCR 0.8
- Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.Eur J Cancer · 201635 citationsRCR 1.2
- 32 citationsRCR 0.7
- First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.Clin Cancer Res · 202120 citationsRCR 1.0